JP2021519069A5 - - Google Patents
Info
- Publication number
- JP2021519069A5 JP2021519069A5 JP2020551499A JP2020551499A JP2021519069A5 JP 2021519069 A5 JP2021519069 A5 JP 2021519069A5 JP 2020551499 A JP2020551499 A JP 2020551499A JP 2020551499 A JP2020551499 A JP 2020551499A JP 2021519069 A5 JP2021519069 A5 JP 2021519069A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hiv
- pbmc
- subset
- pbmcs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024046892A JP2024073653A (ja) | 2018-03-27 | 2024-03-22 | 遺伝子改変リンパ球の製造方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648804P | 2018-03-27 | 2018-03-27 | |
| US62/648,804 | 2018-03-27 | ||
| PCT/US2019/024410 WO2019191314A1 (en) | 2018-03-27 | 2019-03-27 | Methods of manufacturing genetically-modified lymphocytes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046892A Division JP2024073653A (ja) | 2018-03-27 | 2024-03-22 | 遺伝子改変リンパ球の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519069A JP2021519069A (ja) | 2021-08-10 |
| JP2021519069A5 true JP2021519069A5 (cg-RX-API-DMAC7.html) | 2022-04-04 |
Family
ID=68058501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551499A Pending JP2021519069A (ja) | 2018-03-27 | 2019-03-27 | 遺伝子改変リンパ球の製造方法 |
| JP2024046892A Pending JP2024073653A (ja) | 2018-03-27 | 2024-03-22 | 遺伝子改変リンパ球の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046892A Pending JP2024073653A (ja) | 2018-03-27 | 2024-03-22 | 遺伝子改変リンパ球の製造方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20210015868A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773622A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021519069A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200135852A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019191314A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hivワクチン接種および免疫療法 |
| CA3028982A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| EP3773622A4 (en) * | 2018-03-27 | 2021-12-01 | American Gene Technologies International Inc. | METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES |
| CA3144413A1 (en) * | 2019-07-17 | 2021-01-21 | Rafick-Pierre Sekaly | Long lived t cells for treating hiv infection |
| AU2021232603A1 (en) * | 2020-03-03 | 2022-10-20 | American Gene Technologies International Inc. | On demand expression of exogenous factors in lymphocytes to treat HIV |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292038B2 (en) * | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| US10968451B2 (en) * | 2014-10-14 | 2021-04-06 | Texas Tech University System | Multiplexed shRNAs and uses thereof |
| GB201509202D0 (en) * | 2015-05-28 | 2015-07-15 | Ge Healthcare Bio Sciences Ab | Semi-static cell culture |
| US11980663B2 (en) * | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| JP7153332B2 (ja) * | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hivワクチン接種および免疫療法 |
| CA3028982A1 (en) * | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| US10772887B2 (en) * | 2016-08-03 | 2020-09-15 | Kagoshima University | Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) |
| EP3773622A4 (en) * | 2018-03-27 | 2021-12-01 | American Gene Technologies International Inc. | METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES |
-
2019
- 2019-03-27 EP EP19777212.2A patent/EP3773622A4/en active Pending
- 2019-03-27 JP JP2020551499A patent/JP2021519069A/ja active Pending
- 2019-03-27 US US17/042,043 patent/US20210015868A1/en not_active Abandoned
- 2019-03-27 KR KR1020207030636A patent/KR20200135852A/ko not_active Ceased
- 2019-03-27 WO PCT/US2019/024410 patent/WO2019191314A1/en not_active Ceased
-
2023
- 2023-07-28 US US18/227,747 patent/US20240115604A1/en not_active Abandoned
-
2024
- 2024-03-22 JP JP2024046892A patent/JP2024073653A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240091339A1 (en) | Pre-immunization and immunotherapy | |
| US20240252615A1 (en) | Pre-immunization and immunotherapy | |
| Del Prete et al. | Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies | |
| US10888613B2 (en) | Method of producing cells resistant to HIV infection | |
| JP2025098175A (ja) | 事前の免疫化ステップのないhiv免疫療法 | |
| JP2019527055A5 (cg-RX-API-DMAC7.html) | ||
| US20240115604A1 (en) | Methods of manufacturing genetically-modified lymphocytes | |
| Olbrich et al. | Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs | |
| Liu et al. | CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals | |
| WO2021178571A1 (en) | On demand expression of exogenous factors in lymphocytes to treat hiv | |
| RU2465324C1 (ru) | Способ генерации специфического иммунного ответа против антигенов вируса иммунодефицита человека | |
| WO2025050047A1 (en) | Combination immunotherapy and antiviral treatment | |
| WO2025064901A2 (en) | Hiv vaccination and immunotherapy | |
| Pike | The role of CD4+ T cells in Friend virus infection |